When osimertinib (EGFR target mutant inhibitor) was combined with an anti-HER3 monoclonal antibody to treat lung cancer, it promoted IRE1α-dependent upregulation of HER3 and activated cGAS in cancer cells to produce cGAMP, which was later transferred to macrophages and activated the cGAS-STING pathway in macrophages, thereby promoting macrophage Fc receptor-dependent tumor elimination (132). The gene discussed is STING1; the disease is cancer.